Palmitoylethanolamide (PEA) has an obvious appeal to anyone who trains hard. It is anti-inflammatory and analgesic, and unlike ibuprofen it does not work by inhibiting COX enzymes, which is the exact mechanism behind the long-standing concern that regular NSAID use blunts training adaptations. On paper that makes PEA the ideal recovery compound: pain relief without the interference.
Three randomized controlled trials have now tested that idea directly in healthy exercising adults. They do not all agree, and the disagreement is instructive. This article walks through what each one actually measured, because the difference between “reduced a blood biomarker” and “you felt less sore” is the entire story here.
Key Takeaways
- A 2020 trial in 28 healthy males found a single PEA dose reduced post-exercise myoglobin and blood lactate concentrations, but muscle soreness itself was not reported as improved [1].
- A 2024 crossover trial in 11 males found PEA had no effect on muscle soreness, muscle strength, jump performance, creatine kinase, or any molecular marker of damage or regeneration after eccentric exercise [2].
- A 2024 eight-week resistance training trial in 48 adults found no difference in lean mass, higher countermovement jump height in the PEA group, and higher bench press one-rep max in the placebo group [3].
- Across all three, doses were low by the standards of PEA pain research: 167.5 to 350 mg of Levagen+, versus the 600 to 1200 mg daily typical of clinical pain trials.
- The eight-week training study was funded by the ingredient manufacturer, which the authors disclose [3]. That does not invalidate it, but it is context worth having.
Why Anyone Expected PEA to Help Here
Strenuous exercise, particularly eccentric work like lowering a heavy weight under control, causes microstructural muscle damage. That damage triggers an inflammatory response, which produces the delayed-onset muscle soreness most lifters know well, along with a temporary drop in force production that can last several days.
The standard over-the-counter answer is an NSAID, and that answer has a known cost. Because the inflammatory response is part of the repair and adaptation signal, blunting it pharmacologically has been shown in some studies to reduce training gains. PEA works through PPAR-alpha activation and mast cell stabilization rather than COX inhibition, as covered in this site’s mechanism articles, so the hypothesis was that it could reduce the discomfort without touching the adaptation pathway.
That is a genuinely reasonable hypothesis. The trials are where it meets reality.
The 2020 Trial: A Biomarker Signal, Not a Soreness Signal
The first study, published in Nutrients, recruited 28 healthy young males who attended the lab on four consecutive days. They were randomized to a liquid drink containing either 167.5 mg of Levagen+ PEA with maltodextrin, or 1 g of maltodextrin alone as placebo. The exercise protocol was four sets of leg press at 80% of one-rep max plus a performance set. Measurements were taken before and immediately after exercise, then at 1, 2, 3, 24, 48, and 72 hours [1].
The exercise worked as intended: it raised blood lactate, increased muscle soreness and thigh circumference, and elevated biomarkers of muscle damage and TNF-alpha. Against that background, PEA significantly reduced myoglobin and blood lactate concentrations and increased protein kinase B phosphorylation. The authors concluded PEA “may aid in muscle recovery from repeat bouts of exercise performed within a short duration.”
Notice what is and is not in that list. Myoglobin is a protein released from damaged muscle into the bloodstream, so a lower value is consistent with less damage. But the outcome an athlete cares about, how sore you feel and how much force you can produce tomorrow, is not where the significant findings landed. A biomarker moving in a favorable direction is a reason to run a bigger study, not a reason to conclude the supplement works for the thing people buy it for.
The 2024 Crossover Trial: A Clear Null Result
The most directly damaging finding for the recovery hypothesis came from KU Leuven, published in Medicine and Science in Sports and Exercise under a title that leaves little ambiguity: “Palmitoylethanolamide Does Not Affect Recovery from Exercise-Induced Muscle Damage in Healthy Males.”
Eleven healthy males completed a double-blind crossover in which they received either 350 mg Levagen+ PEA or maltodextrin placebo in randomized order. In each condition they performed an acute bout of 24 sets of 10 eccentric knee extension contractions on an isokinetic dynamometer, which is a deliberately punishing protocol. Maximal voluntary contraction and jump height were measured at baseline and at 24, 48, 72, and 120 hours. Blood was drawn daily, and muscle biopsies were taken at baseline and 48 hours. Soreness, sleep quality, and food intake were logged daily [2].
The protocol did its job: strength dropped by around 40%, jump height by around 17%, and creatine kinase and perceived soreness both rose. PEA changed none of it. No effect on soreness, no effect on strength recovery, no effect on jump performance, and no effect on local or systemic markers of muscle damage, catabolism, or regeneration [2].
The obvious limitation is the sample size of 11. But this was a crossover design, which is considerably more statistically efficient than a parallel-group study of the same size, and the muscle biopsy data means the null result holds at the tissue level and not just the questionnaire level. When a study measures that many outcomes across five days and finds nothing on any of them, that is a meaningful null.
The Eight-Week Training Trial: A More Complicated Picture
The third study asked a different and arguably more important question. Rather than a single damaging bout, it tested whether taking PEA across an entire training block affects the adaptations you are training for.
Published in Sports Medicine Open, it randomized 52 untrained but recreationally active adults aged 18 to 35 to either 350 mg Levagen+ (equivalent to 300 mg PEA) daily or matched maltodextrin capsules, alongside eight weeks of whole-body resistance training. Forty-eight participants were included in the intention-to-treat analysis [3].
Three findings, in order of how much they matter:
First, there were no significant between-group differences in total or regional lean body mass. PEA did not build more muscle, and it did not appear to interfere with building muscle, which was the primary question given the NSAID concern that motivated the study.
Second, countermovement jump height was significantly higher in the PEA group at week 10, by roughly 2.9 cm.
Third, and this one rarely appears in supplement marketing, one-rep max bench press was significantly higher in the placebo group, by roughly 2.2 to 2.7 kg depending on the analysis [3]. No treatment effects were found for any other outcome, including sleep, wellbeing, or exercise-associated pain.
A result where one performance measure favors the supplement and another favors placebo, with no effect on the primary outcome, is most honestly read as noise across multiple comparisons rather than a real divergent effect on jumping versus pressing. The authors’ own conclusion was appropriately narrow: PEA did not impair lean mass gains, and produced higher lower-body power. The study was funded by Gencor Pacific, the Levagen+ manufacturer, which the authors disclose.
Reading the Three Together
The pattern across these trials is a compound with a plausible mechanism, a possible signal on blood biomarkers of damage, and no reliable effect on the outcomes people actually train around: soreness, strength recovery, and hypertrophy.
There is one methodological thread worth pulling. All three studies used 167.5 to 350 mg of Levagen+. The clinical pain literature on PEA, including the neuropathic pain and fibromyalgia trials covered elsewhere on this site, generally uses 600 to 1200 mg per day of micronized or ultramicronized PEA, often for weeks rather than as a single dose. It is entirely possible that these exercise studies tested a dose too low and a duration too short to reproduce the effect seen in chronic pain conditions. It is also possible that acute exercise-induced soreness is simply a different phenomenon from chronic neuroinflammatory pain, and that a compound which helps one has no reason to help the other. Nothing published resolves which explanation is right.
What can be said cleanly: as of now, no trial has demonstrated that PEA reduces muscle soreness or speeds strength recovery in healthy trained people, and the single study that looked hardest for such an effect found none.
Frequently Asked Questions
Does PEA interfere with muscle growth the way NSAIDs might?
The eight-week resistance training study found no difference in lean body mass between PEA and placebo, so there is no evidence of interference [3]. That is a real, if modest, point in PEA’s favor compared with routine NSAID use.
Would a higher dose work better for soreness?
Unknown. The exercise trials used 167.5 to 350 mg, well below the 600 to 1200 mg daily used in most PEA pain research. No study has tested a clinical-range dose against exercise-induced soreness.
Should I take PEA before or after training?
There is no evidence-based answer, because no trial has established a benefit whose timing could be optimized. The 2020 study dosed before exercise; the 2024 crossover dosed as a supplementation protocol. Neither found a soreness effect to time around.
Is Levagen+ different from regular PEA for this purpose?
Levagen+ is a bioavailability-optimized branded PEA ingredient covered in detail in this site’s Levagen+ article. All three exercise trials used it, so the null results are not attributable to using a poorly absorbed form.
What does PEA actually seem to do after exercise?
The clearest replicated finding is a reduction in circulating myoglobin and lactate in one trial [1]. Whether that translates to anything a person notices has not been demonstrated.
References
- Mallard A, Briskey D, Richards A, Mills D, Rao A. The Effect of Orally Dosed Levagen+ (palmitoylethanolamide) on Exercise Recovery in Healthy Males: A Double-Blind, Randomized, Placebo-Controlled Study. Nutrients (2020). PMID 32106527
- Schouten M, Dalle S, Costamagna D, et al. Palmitoylethanolamide Does Not Affect Recovery from Exercise-Induced Muscle Damage in Healthy Males. Med Sci Sports Exerc (2024). PMID 39086058
- Huschtscha Z, Silver J, Gerhardy M, et al. The Effect of Palmitoylethanolamide (PEA) on Skeletal Muscle Hypertrophy, Strength, and Power in Response to Resistance Training in Healthy Active Adults: A Double-Blind Randomized Control Trial. Sports Med Open (2024). PMID 38844675
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
